Business
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the second tranche of its non-brokered private placement of up to 12,000,000 units (the "Units") at a price of $0.125 ...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the second tranche of its non-brokered private placement of up to 12,000,000 units (the "Units") at a price of $0.125 per Unit for gross proceeds of up to $1,500,000 (the "Offering").","length":579,"tagName":"p"},{"type":"text","content":"The second tranche closing of the Offering resulted in the issuance of 150,000 Units for gross proceeds of $18,750.00. Each Unit is comprised of one Common Share in the capital of the Company and one Warrant. Also, in connection with the second tranche closing of the Offering, the Company paid finders fees of $1,312.50 in cash commission and issued 10,500 finder's warrants to certain finders. Each finder's warrant is exercisable to acquire one Common Share at a price of $0.175 per share for a period of two years from the date of issuance. Acumen Capital Finance Partners Limited acted as sole finder in connection with the second tranche closing of the Offering.","length":676,"tagName":"p"},{"type":"text","content":"The Company also wishes to announce that its press release of March 28, 2025 erroneously reported that finders' fees and finders' warrants were paid to Abinvest Corporation and Abingdon Capital Corp. The Company confirms that no finders' fees or finders' warrants were paid to either Abinvest Corporation or Abingdon Capital Corp. in relation to the Offering.","length":375,"tagName":"p"},{"type":"text","content":"The Offering is being made to accredited investors or to such other qualified persons under such other prospectus exemptions as the Company may approve, provided however, that the Offering will not be made to persons or pursuant to securities laws exemptions that would require either the preparation or the filing of a prospectus, offering memorandum or similar document by the Company.","length":387,"tagName":"p"},{"type":"text","content":"The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus on...